Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China
Sep 1, 2018, 00:00
10.1016/j.jval.2018.07.484
https://www.valueinhealthjournal.com/article/S1098-3015(18)32841-9/fulltext
Title :
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir (3D Regimen) for Treatment of Chronic Hepatitis C Genotype 1B Patients in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32841-9&doi=10.1016/j.jval.2018.07.484
First page :
Section Title :
Open access? :
No
Section Order :
423